AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2759945
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg, twice daily for 5 days)
Trial: 785691
Drug: Defibrase (snake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrase (snake venom enzyme) administered daily for 3 weeks
Trial: 28319018
Drug: Elevated serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated serum progesterone (≥4.6 nmol/l)
Trial: 26087584
Drug: Stimulant mesocarb
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant mesocarb
Trial: 26087584
Drug: Nootropic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nootropic and anxiolytic fenibut
Trial: 26087584
Drug: Tranquilizer fenazepam
RxNorm normalized name: medazepam
DrugBank: Medazepam (DB13437)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranquilizer fenazepam
Trial: 24284358
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy (SET) after percutaneous transluminal angioplasty (PTA)
Trial: 16243460
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with 0.30% retinol for 21 days
Trial: 16243460
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with 0.55% retinyl palmitate for 21 days
Trial: 16243460
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of 10,000 IU retinyl palmitate
Trial: 16243460
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of 30,000 IU retinyl palmitate
Trial: 12827681
Drug: Adjuvant postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant postoperative radiation therapy (RT) at 50 Gy in daily fractions of 2 Gy, 5 days/week for 5 weeks
Trial: 12827681
Drug: Sequential postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential postoperative RT plus chemotherapy (CT) with 5-FU (450 mg/sqm/day i.v. bolus, days 1-5) and LEV (150 mg/day orally, days 1-3)
Trial: 12827681
Drug: Adjuvant postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant postoperative radiation therapy (RT) alone
Trial: 12827681
Drug: Sequential postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential postoperative RT and CT
Trial: 11018607
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm (nifedipine XL, prednisone, trimethoprim/sulfa, plain acetaminophen)
Trial: 11018607
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (ketorolac, oxycodone, acetaminophen, prochlorperazine)
Trial: 1501619
Drug: Carrot-rice based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot-rice based rehydration solution (Na 57 mmol/L)
Trial: 1501619
Drug: High-Na glucose
RxNorm normalized name: glucose / sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Na glucose electrolyte solution (Na 90 mmol/L)
Trial: 1501619
Drug: Low-Na glucose
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Na glucose electrolyte solution (Na 55 mmol/L)
Trial: 6371575
Drug: Neurotropic drug
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotropic drug (3 X 200 mg EMD 21657)
Trial: 30821053
Drug: Evolocumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (both dosing regimens)
Trial: 24090993
Drug: Deep massage
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep massage therapy to posterior calf muscles and neural mobilization with self-stretch exercise program (DMS)
Trial: 11777715
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium (10 IU/mL) in irrigation solution
Trial: 11777715
Drug: Standard irrigating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard irrigating solution without heparin sodium
Trial: 11739983
Drug: Aspirin users
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin users (509 patients)
Trial: 11739983
Drug: Aspirin users
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin users and Nonusers
Trial: 9406835
Drug: Alpha-blocker (terazosin)
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker (terazosin) 2 mg/d for 6 months
Trial: 9406835
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet for 6 months
Trial: 9270083
Drug: Alpha-blocker (terazosin)
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker (terazosin)
Trial: 8500302
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone or intravenous methylprednisolone followed by oral prednisone
Trial: 29705468
Drug: Control CNP
RxNorm normalized name: TransCon CNP
DrugBank: ACP-015 (DB17824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control CNP group (discouraged from using analgesics, allowed paracetamol)
Trial: 27717552
Drug: NPC‐01 (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC‐01 (0.02 mg ethinyl estradiol and 1 mg norethisterone)
Trial: 25325894
Drug: High aspiration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High aspiration flow rate (40 cc/min; bottle height: 110 cm; vacuum: 400 mm Hg)
Trial: 25325894
Drug: Low aspiration
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low aspiration flow rate (20 cc/min; bottle height: 90 cm; vacuum: 400 mm Hg)
Trial: 20815129
Drug: Medical Nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Nutrition Therapy Program (dietary strategies)
Trial: 18268073
Drug: Thrice-daily BIAsp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily BIAsp 30
Trial: 18268073
Drug: Twice-daily BIAsp
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily BIAsp 30
Trial: 10382879
Drug: Moxifloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (200 mg or 400 mg/day for 7 days)
Trial: 10382879
Drug: Lomefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin (400 mg/day for 7 days)
Trial: 1948834
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen therapy (Estraderm)
Trial: 18368950
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of cefadroxil (500 mg)
Trial: 18368950
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of cefadroxil (500 mg)
Trial: 16572062
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (given twice daily during antibiotic therapy)
Trial: 12658070
Drug: Naloxone in
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone in combination with Clonidine
Trial: 12658070
Drug: Placebo (Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Drug B)
Trial: 9108813
Drug: Clomipramine 75-150
RxNorm normalized name: clomipramine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 75-150 mg/day
Trial: 8475955
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of aspirin from randomization to delivery
Trial: 8475955
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment from randomization to delivery
Trial: 31433347
Drug: KET/DEX (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KET/DEX (0.3 mg/kg bolus followed by 0.15 mg/kg/h infusion of ketamine + 0.7 μg/kg/h infusion of dexmedetomidine for 1.5 hours)
Trial: 31433347
Drug: KET/FENT (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KET/FENT (0.3 mg/kg bolus followed by 0.15 mg/kg/h infusion of ketamine + three 25 μg fentanyl injections for 1.5 hours)
Trial: 15711829
Drug: Cytokine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine treatment (Interleukin-2 and/or interferon)
Trial: 2185340
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy plus standard therapy followed by maintenance cisplatin for 6 months
Trial: 2185340
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatin and bleomycin) plus standard therapy
Trial: 21034839
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of normal saline injected into the knee joint cavity under ultrasonographic guidance
Trial: 21034839
Drug: No joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No joint infusion (control group)
Trial: 17287897
Drug: Famotidine, 20
RxNorm normalized name: Famotidine, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine, 20 mg/day
Trial: 17287897
Drug: Rebamipide, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide, 300 mg/day
Trial: 10767563
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A - sodium chloride (0.9%) at pH 7.2
Trial: 10767563
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B - sodium chloride (0.9%) at pH 5.8
Trial: 10767563
Drug: Formulation C
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation C - Sorensens phosphate buffer (0.06 M) at pH 5.8
Trial: 10767563
Drug: Formulation D
RxNorm normalized name: Complete Formulation D3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation D - Sorensens phosphate buffer (0.13 M) at pH 5.8
Trial: 10767563
Drug: Formulation E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulation E - Sorensens phosphate buffer (0.06 M) adjusted to pH 5.0
Trial: 10767563
Drug: All formulations
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All formulations (A to E)
Trial: 8815751
Drug: Pravastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin + Nicotinic Acid (1.5 g)
Trial: 8815751
Drug: Pravastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin + Nicotinic Acid (2.25 to 3 g)
Trial: 8815751
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Pravastatin + Nicotinic Acid)
Trial: 27449367
Drug: Triadic parent‐infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triadic parent‐infant Relationship Therapy (TRT)
Trial: 21142385
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (antibiotics and percutaneous drainage if necessary, with or without interval appendectomy)
Trial: 21142385
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (study group)
Trial: 18328195
Drug: Tazarotene 0.1
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1 percent cream plus clindamycin 1 percent gel
Trial: 18328195
Drug: Tretinoin 0.025
RxNorm normalized name: TRETINOIN 0.025% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.025 percent gel plus clindamycin 1 percent gel
Trial: 15809121
Drug: Epidural S(+)‐ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural S(+)‐ketamine 0.1 mg/kg
Trial: 15809121
Drug: Epidural S(+)‐ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural S(+)‐ketamine 0.1 mg/kg plus epidural clonidine 0.5 microg/kg
Trial: 11903080
Drug: Combined femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined femoral and sciatic nerve block with obturator nerve block (5 ml 0.75% ropivacaine)
Trial: 11903080
Drug: Combined femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined femoral and sciatic nerve block (15 ml 0.75% ropivacaine to each nerve)
Trial: 7727178
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups pooled
Trial: 25754396
Drug: Ertugliflozin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 10 mg
Trial: 22540407
Drug: Aripiprazole (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (24 mg/day, reduced to 12 mg/day if needed for tolerability)
Trial: 23150126
Drug: Red pepper
RxNorm normalized name: Red pepper
DrugBank: Red pepper (DB14759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red pepper spice (1 g/d)
Trial: 23150126
Drug: Turmeric (2.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric (2.8 g/d)
Trial: 15519008
Drug: CrCl <60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CrCl <60 ml/min
Trial: 15519008
Drug: CrCl 60
RxNorm normalized name: fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CrCl 60 to 89 ml/min
Trial: 15519008
Drug: CrCl >89
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CrCl >89 ml/min
Trial: 11225136
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E capsules 400 units/day
Trial: 11225136
Drug: T. arjuna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T. arjuna tree bark powder 500 mg daily
Trial: 7810184
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection of digoxin (0.8 mg)
Trial: 2112083
Drug: Intravenous portal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous portal chemotherapy for 7 days
Trial: 2112083
Drug: Transfused patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfused patients with chemotherapy
Trial: 2112083
Drug: Neither transfusions
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither transfusions nor chemotherapy
Trial: 333608
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (cephalosporin, 2 gm/day in divided doses for 5 days)
Trial: 333608
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (cephalosporin)
Trial: 31845139
Drug: Intravenous pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pantoprazole 40 mg daily during the fasting period after ESD
Trial: 24903131
Drug: Nebulised budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised budesonide (800 μg)
Trial: 23945072
Drug: Lipegfilgrastim (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipegfilgrastim (6 mg subcutaneous injection on day 2 of each 21-day chemotherapy cycle)
Trial: 23945072
Drug: Pegfilgrastim (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6 mg subcutaneous injection on day 2 of each 21-day chemotherapy cycle)
Trial: 21773781
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant FSH (rFSH) with starting dose of 75-100 IU daily
Trial: 21773781
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) at 100 mg/day for 5 days
Trial: 19341123
Drug: Hyperbaric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric treatment group (33 patients)
Trial: 10047639
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 to 60 mg/day)
Trial: 10047639
Drug: Azosemide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azosemide (60 to 90 mg/day)
Trial: 7762839
Drug: Ketorolac (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (0.9 mg/kg)
Trial: 7762839
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (2 mL)
Trial: 7000260
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily injections of insulin (Monotard plus Actrapid)
Trial: 7000260
Drug: Twice-daily injections
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily injections of insulin (Semitard plus Actrapid)
Trial: 11974458
Drug: Endoscopic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic therapy for palliation by ablation, dilatation, or stenting
Trial: 11974458
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment of postoperative complications
Trial: 11974458
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment of anastomotic strictures
Trial: 30252113
Drug: No interview
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No interview (treatment-as-usual control)
Trial: 17512015
Drug: N2O and
RxNorm normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N2O and oxygen inhalation (group 1)
Trial: 16240961
Drug: Prompt L‐Pop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt L‐Pop (PLP)
Trial: 11906359
Drug: High-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose subcutaneous birch pollen immunotherapy (IT)
Trial: 10434231
Drug: Valganciclovir 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir 360 mg
Trial: 10434231
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 1000 mg
Trial: 10434231
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir 5 mg/kg
Trial: 2140848
Drug: Oral loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral loading with L-tryptophan
Trial: 2140848
Drug: Tricyclic antidepressant
RxNorm normalized name: Tricyclic antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressant treatment
Trial: 25456867
Drug: Prolastin C
RxNorm normalized name: PROLASTIN C 1000mg Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin C (human plasma-derived AAT) at 60 mg/kg infused intravenously within 12 hours of admission
Trial: 21853425
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole (group A)
Trial: 21853425
Drug: Fluconazole nasal
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole nasal spray (group B)
Trial: 21853425
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral itraconazole and nasal fluconazole (group C)
Trial: 21853425
Drug: Irrigation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigation with fluconazole solution (group D)
Trial: 21853425
Drug: Convenient medical
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Convenient medical treatment only (group E)
Trial: 19663129
Drug: Budesonide/formoterol pMDI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI, 80/4.5 microg (320/18 microg/d) twice daily
Trial: 19663129
Drug: Budesonide/formoterol pMDI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI, 160/4.5 microg (320/9 microg/d) once daily
Trial: 19663129
Drug: Budesonide/formoterol pMDI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI, 80/4.5 microg (160/9 microg/d) once daily
Trial: 19663129
Drug: Budesonide pMDI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide pMDI, 160 microg (320 microg/d) once daily
Trial: 16323085
Drug: Famciclovir (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir (1000 mg given twice daily)